Among Patients Taking Beta-Adrenergic Blockade Therapy, Use Measured (Not Predicted) Maximal Heart Rate to Calculate a Target Heart Rate for Cardiac Rehabilitation.


Journal

Journal of cardiopulmonary rehabilitation and prevention
ISSN: 1932-751X
Titre abrégé: J Cardiopulm Rehabil Prev
Pays: United States
ID NLM: 101291247

Informations de publication

Date de publication:
01 11 2023
Historique:
pmc-release: 01 11 2024
medline: 30 10 2023
pubmed: 13 6 2023
entrez: 13 6 2023
Statut: ppublish

Résumé

Among patients in cardiac rehabilitation (CR) on beta-adrenergic blockade (βB) therapy, this study describes the frequency for which target heart rate (THR) values computed using a predicted maximal heart rate (HR max ), correspond to a THR computed using a measured HR max in the guideline-based heart rate reserve (HR reserve ) method. Before CR, patients completed a cardiopulmonary exercise test to measure HR max , with the data used to determine THR via the HR reserve method. Additionally, predicted HR max was computed for all patients using the 220 - age equation and two disease-specific equations, with the predicted values used to calculate THR via the straight percent and HR reserve methods. The THR was also computed using resting heart rate (HR) +20 and +30 bpm. Mean predicted HR max using the 220 - age equation (161 ± 11 bpm) and the disease-specific equations (123 ± 9 bpm) differed ( P < .001) from measured HR max (133 ± 21 bpm). Also, THR computed using predicted HR max resulted in values that were infrequently within the guideline-based HR reserve range calculated using measured HR max . Specifically, 0 to ≤61% of patients would have had an exercise training HR that fell within the guideline-based range of 50-80% of measured HR reserve . Use of standing resting HR +20 or +30 bpm would have resulted in 100% and 48%, respectively, of patients exercising below 50% of HR reserve . A THR computed using either predicted HR max or resting HR +20 or +30 bpm seldom results in a prescribed exercise intensity that is consistent with guideline recommendations for patients in CR.

Identifiants

pubmed: 37311037
doi: 10.1097/HCR.0000000000000806
pii: 01273116-990000000-00099
pmc: PMC10615658
mid: NIHMS1897618
doi:

Substances chimiques

Adrenergic Agents 0

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

427-432

Subventions

Organisme : NHLBI NIH HHS
ID : R33 HL143099
Pays : United States
Organisme : NHLBI NIH HHS
ID : R61 HL143099
Pays : United States

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.

Déclaration de conflit d'intérêts

The authors declare no conflicts of interest.

Références

Med Sci Sports. 1975 Winter;7(4):295-8
pubmed: 1235153
Am Heart J. 2008 Aug;156(2):292-300
pubmed: 18657659
J Cardiopulm Rehabil. 2006 Mar-Apr;26(2):72-5; quiz 76-7
pubmed: 16569971
Am J Cardiol. 2016 Apr 15;117(8):1236-41
pubmed: 26897640
Eur J Prev Cardiol. 2016 Nov;23(16):1715-1733
pubmed: 27353128
J Cardiopulm Rehabil Prev. 2022 Sep 1;42(5):359-365
pubmed: 35185145
Curr Opin Cardiol. 2014 Sep;29(5):475-80
pubmed: 25010379
JACC Heart Fail. 2013 Dec;1(6):514-22
pubmed: 24622004
J Cardiopulm Rehabil Prev. 2020 Sep;40(5):E31-E51
pubmed: 32868658
Am Heart J. 2004 Nov;148(5):910-4
pubmed: 15523326
Med Sci Sports Exerc. 2002 Mar;34(3):418-22
pubmed: 11880804
J Am Coll Cardiol. 2003 Dec 17;42(12):2139-43
pubmed: 14680741
Med Sci Sports Exerc. 2008 Jul;40(7):1336-43
pubmed: 18580415
Eur J Prev Cardiol. 2013 Apr;20(2):376-82
pubmed: 22345697
J Cardiopulm Rehabil Prev. 2008 Jan-Feb;28(1):24-30; quiz 31-2
pubmed: 18277826
J Cardiopulm Rehabil Prev. 2018 May;38(3):139-146
pubmed: 29697494
J Cardiopulm Rehabil. 2004 May-Jun;24(3):178-84; quiz 185-6
pubmed: 15235299
J Am Coll Cardiol. 2014 Feb 4;63(4):380-406
pubmed: 24355759
Am Heart J. 2018 Oct;204:76-82
pubmed: 30081276
J Cardiovasc Nurs. 2015 Mar-Apr;30(2):164-71
pubmed: 24866048
Med Sci Sports Exerc. 2012 Mar;44(3):371-6
pubmed: 21900844
Mayo Clin Proc. 2016 Feb;91(2):149-56
pubmed: 26848001
Circ Heart Fail. 2012 Sep 1;5(5):579-85
pubmed: 22773109
Can J Cardiol. 2017 Jun;33(6):777-784
pubmed: 28434533
J Am Coll Cardiol. 2002 Oct 16;40(8):1531-40
pubmed: 12392846

Auteurs

Steven J Keteyian (SJ)

Division of Cardiovascular Medicine, Henry Ford Health, Detroit, Michigan (Drs Keteyian, Kerrigan, Ehrman, and Brawner, Mss Steenson, Grimshaw, and Koester-Qualters, and Messrs Mandel and Berry); and Department of Public Health Sciences, Henry Ford Health, Detroit, Michigan (Dr Peterson).

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH